The Experts below are selected from a list of 36609 Experts worldwide ranked by ideXlab platform
Heng-jun Gao - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of Argonaute protein as a Predictive Marker for human clear cell renal cell carcinoma
International journal of clinical and experimental pathology, 2013Co-Authors: Min Liu, Yuan Feng, Jian-ping Che, Guang-chun Wang, Junhua Zheng, Heng-jun GaoAbstract:Argonaute subfamily proteins are involved in human organ growth and development. Recent studies found its association with human breast cancer, however, its expression profile and its prognostic value in clear cell renal cancer (ccRCC) have not been investigated. Methods: Expression of the Argonaute proteins were assessed by immunohistochemistry (IHC) in tissue microarrays (TMA), containing paired tumor tissue and adjacent non-cancer tissue from 176 patients who had undergone surgery in hospital for histologically proven ccRCC. Prognostic value and correlation with other clinico-pathologic factors were evaluated in two classifications. Results: Data showed a significant higher expression of Argonaute 1 and Argonaute 2 present in neoplastic tissues compared with that in adjacent tissue; A significant correlation existed between the higher expression of Argonaute 1 protein with the T stage, lymph node metastasis and clinical TNM (cTNM); Survival analysis by Kaplan-Meier survival curve and log-rank test demonstrated that elevated Argonaute 1 and Argonaute 2 expression in cancer tissue predicted poorer overall survival (OS) compared with group in lower expression (36.3% VS 67.1%; 37.3% VS 53.9%; respectively). Notably, multivariate analyses by Cox’s proportional hazard model revealed that expression of Argonaute 2 was an independent prognostic factor in renal cancer. Conclusions: In summary, our present study clarify that the aberrant expression of Argonaute in human RCC is possibly involved with tumorigenesis and development, and the Argonaute protein could act as a potential bioMarker for prognosis assessment of renal cancer. Related mechanism is worthy of further investigation.
-
the piwi protein acts as a Predictive Marker for human gastric cancer
International Journal of Clinical and Experimental Pathology, 2012Co-Authors: Yang Wang, Yanxia Liu, Xiaoying Shen, Xiaoyan Zhang, Ximei Chen, Changqin Yang, Heng-jun GaoAbstract:Purpose To investigate the expression of the human PIWI subfamily proteins in gastric cancer and their potential roles in the occurrence, development and prognosis of gastric cancer.
Gustav Ullenhag - One of the best experts on this subject based on the ideXlab platform.
-
tumoral cubilin is a Predictive Marker for treatment of renal cancer patients with sunitinib and sorafenib
Journal of Cancer Research and Clinical Oncology, 2017Co-Authors: Marjut Niinivirta, Gunilla Enblad, Anca Dragomir, Gustav Ullenhag, Per-henrik Edqvist, Fredrik PontenAbstract:Purpose Tyrosine kinase inhibitors like sunitinib and sorafenib are commonly used to treat metastatic renal cell cancer patients. Cubilin is a membrane protein expressed in the proximal renal tubul ...
Marjut Niinivirta - One of the best experts on this subject based on the ideXlab platform.
-
tumoral cubilin is a Predictive Marker for treatment of renal cancer patients with sunitinib and sorafenib
Journal of Cancer Research and Clinical Oncology, 2017Co-Authors: Marjut Niinivirta, Gunilla Enblad, Anca Dragomir, Gustav Ullenhag, Per-henrik Edqvist, Fredrik PontenAbstract:Purpose Tyrosine kinase inhibitors like sunitinib and sorafenib are commonly used to treat metastatic renal cell cancer patients. Cubilin is a membrane protein expressed in the proximal renal tubul ...
Hirokazu Komatsu - One of the best experts on this subject based on the ideXlab platform.
-
the value of serum wisteria floribunda agglutinin positive human mac 2 binding protein as a Predictive Marker for hepatitis c virus related complications after systemic chemotherapy
International Journal of Hematology, 2016Co-Authors: Haruhito Totani, Shigeru Kusumoto, Yasuhito Tanaka, Nana Suzuki, Shinya Hagiwara, Shiori Kinoshita, Etsuko Iio, Asahi Ito, Takashi Ishida, Hirokazu KomatsuAbstract:Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) was developed recently as a Predictive Marker of progression to liver fibrosis and hepatocellular carcinoma (HCC) in patients seropositive for hepatitis C virus (HCV). We retrospectively analyzed 16 HCV-seropositive patients who received systemic chemotherapy for hematologic malignancies to evaluate the usefulness of WFA+-M2BP for predicting HCV-related complications. These were defined as the onset of significant liver damage (LD) with increased HCV RNA levels, leading to interrupted or discontinued chemotherapy or the occurrence of HCC after chemotherapy. Baseline WFA+-M2BP levels were determined using preserved serum samples. The median level of WFA+-M2BP was 1.59 [cutoff index (C.O.I.) value range 0.38–6.66]. With a median follow-up of 623 days (range 120–2404), LD and HCC were observed in three and two patients, respectively. Detectable HCV RNA and WFA+-M2BP ≥2.0 C.O.I. at baseline were identified as risk factors for these HCV-related complications (P = 0.034 and P = 0.005, respectively). The sensitivity, specificity, and positive and negative Predictive values of the WFA+-M2BP level (cutoff point: 2.0 C.O.I.) for the occurrence of HCV-related complications were 100.0, 81.8, 71.4, and 100.0 %, respectively. WFA+-M2BP may be a useful Marker for the prediction of HCV-related complications in HCV-seropositive patients following systemic chemotherapy.
Dominique Helleyrussick - One of the best experts on this subject based on the ideXlab platform.
-
soluble cd146 is a Predictive Marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
Theranostics, 2018Co-Authors: Maeva Dufies, Marie Nollet, Wael Traboulsi, Damien Ambrosetti, Julien Viotti, Delphine Borchiellini, Renaud Grepin, Julien Parola, Sandy Giuliano, Dominique HelleyrussickAbstract:The objective of the study was to use CD146 mRNA to predict the evolution of patients with non-metastatic clear cell renal cell carcinoma (M0 ccRCC) towards metastatic disease, and to use soluble CD146 (sCD146) to anticipate relapses on reference treatments by sunitinib or bevacizumab in patients with metastatic ccRCC (M1). Methods: A retrospective cohort of M0 patients was used to determine the prognostic role of intra-tumor CD146 mRNA. Prospective multi-center trials were used to define plasmatic sCD146 as a Predictive Marker of sunitinib or bevacizumab efficacy for M1 patients. Results: High tumor levels of CD146 mRNA were linked to shorter disease-free survival (DFS) and overall survival (OS). ccRCC patients from prospective cohorts with plasmatic sCD146 variation <120% following the first cycle of sunitinib treatment had a longer progression-free survival (PFS) and OS. The plasmatic sCD146 variation did not correlate with PFS or OS for the bevacizumab-based treatment. In vitro, resistant cells to sunitinib expressed high levels of CD146 mRNA and protein in comparison to sensitive cells. Moreover, recombinant CD146 protected cells from the sunitinib-dependent decrease of cell viability. Conclusion: CD146/sCD146 produced by tumor cells is a relevant biological Marker of ccRCC aggressiveness and relapse on sunitinib treatment.
